Kornimate/medical-research-clean huggingface dataset:
trial to compare effectiveness of 2 insecticides in preventing malaria

Conditions: Malaria

Summary: twenty-four (24) clusters, each containing between 250-300 houses were selected throughout bioko island to be sprayed with either a long lasting pyrethroid insecticide, k-othrine sc 62.5, or a bendiocarb insecticide, ficam. parasite prevalence in children aged 2-14 was measured before and after the application of insecticide.

in 2013, a new long lasting pyrethroid insecticide, k-othrine sc 62.5, that has been developed by bayer ag, was used for the irs program in bioko island, equatorial guinea, for the first time. this change coincided with a marked increase in parasite prevalence in 2-14 year olds as measured in the annual malaria indicator survey (14% to 28%, respectively). in order to determine whether the change in insecticide caused the increase in prevalence, a cluster randomized control trial was designed. twenty-four (24) clusters, each containing between 250-300 houses were selected throughout bioko island. clusters were chosen with an attempt to maximize the geographical space between clusters (to minimize possible residual effects from insecticides), while ensuring that areas with historically higher acceptance rates for indoor residual spraying (irs) were selected. each cluster had a buffer zone of 300m (or halfway between clusters less than 600m apart). a team of 10 local surveyors conducted a baseline survey in each cluster area, measuring prevalence through malaria rapid diagnostic test (rdt) positivity, net ownership, spray coverage, and hemoglobin levels. approximately 100 children in each cluster were tested. these data were then used for a restricted randomization. each cluster was then sprayed with either deltamethrin or bendiocarb, depending on randomization. the irs team put equal amount of effort into each cluster, as determined by number of sprayers/house/day in an attempt to minimize bias. an end-line survey was conducted using an odk collect application in the same cluster areas. prevalence was measured by rdt, and hemoglobin data was gathered. in addition, the head of household was asked about the acceptability to irs and their willingness to receive the insecticide in a future round.

Eligibility criteria:
inclusion criteria: * children between 2-14 years old who reside in a household within the intervention area * household clusters chosen among those with historically high irs acceptance rate * household clusters chosen to maximize distance between clusters. exclusion criteria: * areas with historically high rates of refusing irs
ai echocardiographic screening of cardiac amyloidosis

Conditions: Cardiac Amyloidosis

Summary: recent advances in machine learning and image processing techniques have shown that machine learning models can identify features unrecognized by human experts and accurately assess common measurements made in clinical practice. echocardiography is the most common form of cardiac imaging and is routinely and frequently used for diagnosis. however, there is often subjectivity and heterogeneity in interpretation. artificial intelligence (ai)'s ability for precision measurement and detection is important in both disease screening as well as diagnosis of cardiovascular disease. cardiac amyloidosis (ca) is a rare, underdiagnosed disease with targeted therapies that reduce morbidity and increase life expectancy. however, ca is frequently overlooked and confused with heart failure with preserved ejection fraction. some estimates suggest that ca can be as prevalence as 1% in a general population, with even higher prevalence in patients with left ventricular hypertrophy, heart failure, and other cardiac symptoms that might prompt echocardiography. ai guided disease screening workflows have been proposed for rare diseases such as cardiac amyloidosis and other diseases with relatively low prevalence but significant human impact with targeted therapies when detected early. this is an area particularly suitable for ai as there are multiple mimics where diseases like hypertrophic cardiomyopathy, cardiac amyloidosis, aortic stenosis, and other phenotypes might visually be similar but can be distinguished by ai algorithms. the investigators have developed an algorithm, termed echonet-lvh, to identify cardiac hypertrophy and identify patients who would benefit from additional screening for cardiac amyloidosis.


Eligibility criteria:
inclusion criteria: * patients receiving an echocardiogram that is determined to be suspicious by echonet-lvh exclusion criteria: * patients that decline consent * patients receiving an echocardiogram that is determined to be not suspicious by echonet-lvh
pelvic imrt with tomotherapy: a phase i feasibility study in post-hysterectomy cervical cancer patients

Conditions: Uterine Cervical Neoplasms

Summary: indications for post-hysterectomy radiation therapy (rt) have been well established by clinical data. adjuvant rt has demonstrated local control and survival benefit. in patients with nodal disease, adjuvant chemotherapy concurrent with radiation has further improved the clinical outcome. the acute hematological and gastrointestinal toxicity of concurrent chemo-radiotherapy can be quite high, sometimes preventing patients from completed their full treatment course, potentially compromising the therapeutic benefit of treatment. intensity modulated radiation therapy (imrt) is an advanced method of delivering external beam radiation that may minimize the volume of normal tissue irradiated to high dose and thus decrease the risk of normal tissue toxicity. helical tomotherapy is a novel treatment device with sophisticated imaging and treatment delivery features that are optimally suited for imrt. there are retrospective clinical data supporting the use of non-tomotherapy delivered imrt to treat patients with gynecologic cancers. the proposed study will prospectively test whether helical tomotherapy is a feasible method for delivering imrt in post-hysterectomy cervical cancer patients receiving adjuvant rt. here, the question of feasibility is simply one of verifying that target volumes are reliably covered by 'sculpted' imrt high-dose regions. although this is not a treatment effectiveness study, we will also follow the clinical outcome of these patients, including toxicity, local control and survival, in anticipation that this information will be valuable if the treatment modality is judged feasible and will be used for further treatments of this patient population.

patients with cervical cancer receiving post-operative radiotherapy (rt) for high risk features found on pathologic review will be treated with pelvic intensity modulated radiation therapy (imrt). helical tomotherapy will be used to plan and deliver the radiation treatment. treatment volume will include the upper third of the vagina and para-vaginal tissue and the common, external and internal iliac nodal regions. external beam radiation will be delivered in 180 cgy daily fractions to a total dose of 5040 cgy. patients will receive once a day treatment five days a week, for approximately 6 weeks. concurrent chemotherapy and/or intracavitary brachytherapy may be included in the treatment plan at the discretion of the treating physician, consistent with routine clinical practice.

Eligibility criteria:
inclusion criteria: * age \>= 18 * karnofsky performance status of \>= 60 * figo stage i -iib * pathologic confirmation of cervical cancer * status post hysterectomy * patients with local or regional metastases are eligible for this protocol, but not those with distant metastases exclusion criteria: * age \< 18 * karnofsky performance status \< 60 * radiographic or pathologic evidence of distant metastatic disease * prior pelvic radiation therapy, other than trans-vaginal ring brachytherapy irradiation for acute hemostasis
drug utilisation and lifestyle intervention study in patients attending cardiac outpatient clinic

Conditions: Coronary Artery Disease

Summary: this study has two parts: a drug utilization study and a health-related quality of life study.

this study has two parts: a drug utilization study and a health-related quality of life study. drug utilisation study is an open label, cross sectional, descriptive drug utilization analysis of the primary cardiovascular drug classes prescribed to coronary artery disease patients attending cardiology opd of a north india hospital. quality of life study intended to evaluate impact of a mobile based patient education program on the health related quality of life, physical activity and body mass index of coronary artery disease patients. it is a two arm study.

Eligibility criteria:
inclusion criteria: * male or female adults 18 - 75 years of age * diagnosed cased of coronary artery disease * agreeing after informed consent to participate exclusion criteria: * high risk cardiac patients * systemic, orthopedic and/or neurological problems restricting physical activity
the effects of physical activity tele-counseling intervention in post-covid-19 conditions

Conditions: Covid19

Summary: it has been found that physical activity recommendations with telerehabilitation in different disease groups improve the functional capacity, physical activities and mental health of the patients as much as the supervised exercise programs. however, there are no studies in the literature that provide online physical activity counseling in covid-19 patients, and evaluate the effect of physical activity counseling on physical activity level, quality of life, physical performance, fatigue, kinesophobia, pain, dyspnea, mental health and behavior change levels. for this reason, this study aimed to evaluate the effect of online physical activity counseling on physical activity level, quality of life, physical performance, fatigue, kinesophobia, pain, dyspnea, mental health and behavior change level in covid-19 patients.


Eligibility criteria:
inclusion criteria: * individuals who have suffered covid-19 and have passed at 3 months after the polymerase chain reaction (pcr) test turned negative * volunteering to participate in the research exclusion criteria: * having another diagnosed respiratory or cardiac problem * having infections during the evaluation * having a skeletal-muscular disease that may affect the evaluation results * having neurological and psychiatric problems * individuals with restrictions that prevent being physically active during the evaluation and counseling program. * pregnant individuals
vbn-ebus-gs-tblb with or without fluoroscopy for the diagnosis of ppls

Conditions: Lung Cancer

Summary: the purpose of this study is to evaluate the feasibility, efficacy and safety of transbronchial lung biopsy (tblb) and bronchial brushing by using virtual bronchoscopic navigation (vbn) combined with endobronchial ultrasound (ebus) and a guide sheath (gs) for the diagnosis of peripheral pulmonary lesions (ppls) without radiographic fluoroscopy.

the investigators evaluate the feasibility, efficacy and safety of transbronchial lung biopsy (tblb) and bronchial brushing by using virtual bronchoscopic navigation (vbn) combined with endobronchial ultrasound (ebus) and a guide sheath (gs) as a guide for diagnosing peripheral pulmonary lesions (ppls) without radiographic fluoroscopy.the study is designed as a three centers prospective randomized controlled trial.the participating centers are department of endoscopy , shanghai chest hospital, shanghai jiaotong university, china. department of endoscopy, national cancer center/cancer hospital, chinese academy of medical sciences, china. department of respiratory medicine, the first affiliated hospital of guangzhou medical university, china. patients are divided into two groups, vbn-ebus-gs-x-ray group and vbn-ebus-gs group. each subject will be randomized to each group. the study is expected to enroll 436 patients at 3 centers.

Eligibility criteria:
inclusion criteria: * individuals eligible for inclusion are patients that the ct scan appearance of the ppls showed the longest diameter was more than 8mm and non ggo lesions. exclusion criteria: 1. absence of bronchus leading to or adjacent to the lesion from ct scan 2. refusal of participation 3. severe cardiopulmonary dysfunction and other indications that can't receive bronchoscopy 4. presence of concomitant endobronchial lesion during the brochoscopy procerdure

Keywords: virtual bronchoscopic navigation endobronchial ultrasound guide sheath transbronchial biopsy peripheral pulmonary lesions
safety, tolerability, pharmacokinetics and pharmacodynamics of multiple subcutaneous injections of hrs9531 in patients with type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2

Summary: the main purpose of this study is to assess the safety and tolerability of multiple subcutaneous injections of hrs9531 in patients with type 2 diabetes mellitus who have suboptimal glycaemic control after conventional lifestyle or metformin intervention.


Eligibility criteria:
inclusion criteria: 1. males and infertility females, 18-65 years of age, inclusive, on the date of signing informed consent. 2. diagnosed with type 2 diabetes mellitus (t2dm) for at least 6 months. 3. treated with conventional lifestyle intervention alone or stable treatment with metformin (≥1000 mg/day) at least 8 weeks prior to screening. 4. 7.0% ≤ hba1c ≤10.5% at screening. exclusion criteria: 1. history or presence of vital organ primary diseases, including but not limited to neuropsychiatric, cardiovascular, digestive, respiratory, urinary, endocrine, blood, immune and other diseases, judged by researchers to be unsuitable for this study. 2. diagnosed or suspected with type 1 diabetes mellitus, special types of diabetes or secondary diabetes. 3. have a history of acute complications of diabetes (diabetic ketoacidosis, lactic acidosis, hyperglycaemic hyperosmolar state, etc.) or episode of severe hypoglycaemic events within 12 months prior to screening. 4. have a presence of proliferative diabetic retinopathy, diabetic macular edema, or nonproliferative diabetic retinopathy requiring treatment during the trial; 5. participants in clinical trials of any drug or medical device in the 3 months prior to screening. 6. breast-feeding women. 7. the investigator considers that the subject has any other factors that would make it inappropriate to participate in this study.
kinect sensor in cerebral palsy children phase 2.2

Conditions: Cerebral Palsy Children; Upper Extremity Problem

Summary: there are 3 phase of the study. this registration is phase 2.2. this registration will conduct a randomized controlled trial study in the cerebral palsy children. due to the limitation of period of time of grant, we changed the study type into pilot-randomization. our new method of study will collect all of our study which previously separated into pilot and randomized controlled trial in just only one study "pilot-randomization".


Eligibility criteria:
inclusion criteria: * spastic cerebral palsy aged 10-15 years * sufficient cognitive/attention capacity to understand basic instructions * can cooperate with the therapist for short period of time during training * manual ability classification system (macs) 2-3 * zancolli classification of the affected upper extremity was grade i-ii. * give the informed consent exclusion criteria: * inability to understand the instruction and follow the task * severe comorbidities, visual or auditory impairment * had history of botulinum toxin injection on the affected upper extremity for last 6 months or receive the injection during the study time * other treatment options planned on the affected upper extremity during the study time * wear daytime orthosis on the affected limb * zancolli classification of the affected hand was grade iii. * got an epilepsy or convulsive condition * denied to give the informed consent or continue the study

Keywords: video-game kinect sensor upper extremities problems cerebral palsy children
gut flora and lipid metabolism

Conditions: Hypercholesterolemia

Summary: it is well known that metabolic responses to diet and drugs are affected by genetic and environmental factors. still, a large part of differences in responses between individuals remains unexplained. to increase our understanding of individual differences, more and more attention is paid to the role of intestinal microbiota. not only energy and glucose may be related to the microbiota, but also lipid metabolism. this is not surprising as lipid metabolism, glucose metabolism, and obesity are closely linked. there is substantial evidence from in particular animal studies that the gut microbiota is related to lipid and lipoprotein metabolism. however, there is less evidence to what extent modulation of the gut microbiota changes lipid and lipoprotein metabolism in humans.


Eligibility criteria:
inclusion criteria: * aged between 18-70 years * serum total cholesterol: 5-8mmol/l exclusion criteria: * serum triacylglycerol \> 3.0mmol/l * use of oral anticonceptives * pregnant or breastfeeding women * kidney insufficiencies * unstable body weight * allergy to antibiotics * treatment with cholesterol-lowering drugs * use of medication or a medically prescribed diet * active cardiovascular disease * abuse of drugs * more than 21 alcohol consumptions per week for men and 14 consumptions for women * use of an investigational product within the previous 30 days * not willing to stop the consumption of products rich in plant stanol or sterol esters 3 weeks before start of the study * use of gastric acid inhibitors, laxantia, prebiotica, probiotica and antibiotica for at least one month before the start of the study and during the study

Keywords: gut flora antibiotics lipid metabolism ldl cholesterol
use of electronic health records for addressing overweight and obesity in primary care

Conditions: Overweight; Obesity

Summary: overweight and obesity are highly significant clinical and public health issues, affecting more than two-thirds of adults in this country; however, primary care clinicians often do not document overweight or obesity or discuss weight management with their patients. the objectives of the proposed research are to develop and evaluate a set of tools within electronic health records (ehrs) to assist primary care clinicians with the diagnosis and treatment of overweight and obesity and to help patients manage their weight.


Eligibility criteria:
inclusion criteria: * all adult patients (ages \>= 20 years) who have a visit at a primary care practice at brigham and women's hospital during the intervention period

Keywords: overweight obesity body mass index weight primary care
early detection of autism spectrum disorder in children

Conditions: Autism Spectrum Disorder

Summary: rationale: autism spectrum disorder (asd) is defined by deficits in social interaction and communication identified before the age of 3 years. modified checklist for autism in toddlers (m-chat) is a sensitive tool for asd screening in children 16-23 months. a limited number of studies with a small number of patients have documented the developmental profile of children with asd during infancy. retrospective evaluations of videotaped behavior of children with asd at 8 months and at 12 months identified early signs of asd. a few studies found early signs of asd during infancy in siblings of autistic children. data documenting the age of onset and regression in asd is controversial and limited. no large prospective studies documented the specific developmental profile of children with asd starting at 6 months of age. defining a specific autistic pattern on a developmental screening test could help identify infants at risk for asd and improve their outcome through earlier diagnosis and treatment. more recently, genetic tests have been shown to aid in early identification of asd which facilitates earlier intervention. genetic testing among siblings of children with autism can aid in identification of autism or other related disorders in the siblings. purpose: the purpose of this study is to learn about the early signs of autism in siblings of children with autism spectrum disorders. * the investigators will enroll siblings of children with asd. those siblings who completed the red flags for communication scale (rfc) at 6 months and/or at 12 months and failed the rfc at 12 months will be given a genetic screening test. * it is the investigators goal to define a specific autistic pattern on a developmental screening test that could help identify sibling infants at risk for asd and improve their outcome through earlier diagnosis and treatment and to evaluate if the results of the clinical screening test will correlate with the results of the genetic screening test.


Eligibility criteria:
inclusion criteria: * the subject must be a sibling of a child with a previous expert clinical diagnosis of autism spectrum disorder. * subjects will be included for the genetic test if he/she meets the following criteria: * at 12 months of age he/she failed two or more items on the rfc with at least one failed critical item * they have no significant known hearing, vision or motor impairment that will impact on their ability to perform on developmental assessments exclusion criteria: * those children who do not meet the inclusion criteria * those who do not speak english will be excluded from this study.

Keywords: autism siblings genetic test screening